Oral Chemotherapy Safety in Ambulatory Oncology: A Proactive Risk Assessment
门诊肿瘤学中口服化疗的安全性:主动风险评估
基本信息
- 批准号:7363311
- 负责人:
- 金额:$ 19.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-01 至 2009-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by the applicant): Oral chemotherapy is an emerging medication safety hazard in ambulatory oncology. To characterize the nature and magnitude of risk, we propose to complete failure mode and effect analyses for five oral chemotherapy agents, including an improvement plan for addressing the hazards associated with these classes of medications. The study will proceed in four parts. First, researchers will characterize oral chemotherapy-related medication errors and injuries using data from various sources, including prompted physician reporting, patient focus groups, and de-identified incidents reports and root cause analyses elicited from 13 comprehensive cancer centers. Second, the researchers will convene interdisciplinary teams to develop detailed process maps for five oral chemotherapies used by adult and pediatric ambulatory patients at the study site, New England's largest cancer center. Third, the same interdisciplinary team will identify, analyze, and prioritize failure modes associated with five oral chemotherapies. Fourth, the results will be integrated into an improvement plan that includes a portfolio of interventions to address high-priority failure modes. A modified Delphi approach will be employed to facilitate consensus among key organizational
stakeholders -- including patient safety professionals, oncologists, administrative leaders, board members, and cancer patients -- based on the risks and benefits of potential interventions as well as their cost and ease of implementation. Few cancer centers have in place safety precautions for monitoring or managing the risk of oral chemotherapies. Therefore, a structured and high-quality risk assessment in this area may identify opportunities for improvement that could spread quickly in US oncology care. As the use of oral chemotherapy grows, the results of this study may inform practice at a critical time. Lessons about oral chemotherapy safety are applicable to other high-alert medications in ambulatory care.
描述(由申请方提供):口服化疗是门诊肿瘤学中一种新出现的药物安全性风险。为了描述风险的性质和程度,我们建议完成五种口服化疗药物的失效模式和效应分析,包括解决与这些药物类别相关的危害的改进计划。研究将分四个部分进行。首先,研究人员将使用来自各种来源的数据来描述口服化疗相关的用药错误和损伤,包括提示医生报告,患者焦点小组,以及从13个综合癌症中心得出的去识别事件报告和根本原因分析。其次,研究人员将召集跨学科团队,为研究中心(新英格兰最大的癌症中心)的成人和儿科门诊患者使用的五种口服化疗药物制定详细的流程图。第三,同一个跨学科团队将识别,分析和优先考虑与五种口服化疗相关的失败模式。第四,评估结果将纳入一项改进计划,其中包括一系列干预措施,以解决高度优先的故障模式。将采用改进的德尔菲方法,以促进关键组织之间的共识
利益相关者-包括患者安全专业人员,肿瘤学家,行政领导,董事会成员和癌症患者-基于潜在干预措施的风险和收益以及其成本和实施的难易程度。很少有癌症中心采取安全预防措施来监测或管理口服化疗的风险。因此,在这一领域进行结构化和高质量的风险评估可能会发现改进的机会,这些机会可能会在美国肿瘤治疗中迅速传播。随着口服化疗的使用越来越多,这项研究的结果可能会在关键时刻为实践提供信息。关于口服化疗安全性的经验教训适用于门诊护理中的其他高警戒药物。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SAUL N WEINGART其他文献
SAUL N WEINGART的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SAUL N WEINGART', 18)}}的其他基金
相似海外基金
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer
评估联合系统化疗和多轮内镜超声引导射频消融治疗胰腺癌的安全性和有效性的单组 II 期研究
- 批准号:
10743356 - 财政年份:2023
- 资助金额:
$ 19.4万 - 项目类别:
Genetic Biocontainment Switch to Improve the Safety of Drug Detoxifying Bacteria in Preventing Chemotherapy-induced Diarrhea
基因生物防护开关提高药物解毒细菌预防化疗引起的腹泻的安全性
- 批准号:
10698718 - 财政年份:2023
- 资助金额:
$ 19.4万 - 项目类别:
Multi-Modal Interprofessional Training to Improve Chemotherapy Safety
多模式跨专业培训以提高化疗安全性
- 批准号:
9278402 - 财政年份:2017
- 资助金额:
$ 19.4万 - 项目类别:
Multi-Modal Interprofessional Training to Improve Chemotherapy Safety
多模式跨专业培训以提高化疗安全性
- 批准号:
10251286 - 财政年份:2017
- 资助金额:
$ 19.4万 - 项目类别:
Multi-Modal Interprofessional Training to Improve Chemotherapy Safety
多模式跨专业培训以提高化疗安全性
- 批准号:
9767553 - 财政年份:2017
- 资助金额:
$ 19.4万 - 项目类别:
Safety and Effectiveness of Induction Chemotherapy Followed by Brachytherapy for Thick Oral Cancer
诱导化疗后近距离放射治疗厚型口腔癌的安全性和有效性
- 批准号:
15K09990 - 财政年份:2015
- 资助金额:
$ 19.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving healthcare outcomes for cancer patients by increasing quality, safety and efficiency of IV Chemotherapy services
通过提高静脉化疗服务的质量、安全性和效率来改善癌症患者的医疗保健结果
- 批准号:
102114 - 财政年份:2015
- 资助金额:
$ 19.4万 - 项目类别:
Collaborative R&D
Personalized cancer chemotherapy: efficacy and safety based on pharmacokinetics and pharmacogenetics
个性化癌症化疗:基于药代动力学和药物遗传学的疗效和安全性
- 批准号:
25460202 - 财政年份:2013
- 资助金额:
$ 19.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of an integrated system for assuring care quality aiming at safety improvement of oncology emergency in outpatient chemotherapy
开发保障护理质量的综合系统,旨在提高门诊化疗肿瘤急诊的安全性
- 批准号:
23249090 - 财政年份:2011
- 资助金额:
$ 19.4万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Drug utilization study and safety evaluation based on prediction approach for drug interactions in chemotherapy
基于化疗药物相互作用预测方法的药物利用研究及安全性评价
- 批准号:
22790511 - 财政年份:2010
- 资助金额:
$ 19.4万 - 项目类别:
Grant-in-Aid for Young Scientists (B)